Shuangshen Ningxin capsules ameliorate diabetic cardiomyopathy in mice by inhibiting ferroptosis via the NRF2/HO-1 signaling pathway
American Journal of Translational Research · 2026 · 18 (2) · 1719-1731
DOI: 10.62347/dlrz8628 ↗Kurz gefasst
Fachartikel in der Zeitschrift American Journal of Translational Research, 2026. Verfasst von Yitong Cheng und 5 weiteren Autor:innen. Beteiligte Einrichtung: Beijing University of Chinese Medicine Beijing 100105, China. Die Arbeit wurde bisher 1-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Beijing University of Chinese Medicine Beijing 100105, China.
- Institute of Basic Medical Sciences, Xiyuan Hospital, China Academy of Chinese Medical Sciences Beijing 100091, China.
- The Research Center of The Affiliated Hospital to Changchun University of Chinese Medicine Changchun 130021, Jilin, China.
Zitieren
APA
Cheng, Y., Li, L., Xu, S., Zhang, X., Li, C., & Fu, J. (2026). Shuangshen Ningxin capsules ameliorate diabetic cardiomyopathy in mice by inhibiting ferroptosis via the NRF2/HO-1 signaling pathway. American Journal of Translational Research, 18(2), 1719-1731. https://doi.org/10.62347/dlrz8628
Vancouver
Cheng Y, Li L, Xu S, Zhang X, Li C, Fu J. Shuangshen Ningxin capsules ameliorate diabetic cardiomyopathy in mice by inhibiting ferroptosis via the NRF2/HO-1 signaling pathway. American Journal of Translational Research. 2026;18(2):1719-1731. doi:10.62347/dlrz8628
BibTeX
@article{Cheng2026,
author = {Cheng, Yitong and Li, Lanlan and Xu, Shujuan and Zhang, Xiaoqing and Li, Chikun and Fu, Jianhua},
title = {Shuangshen Ningxin capsules ameliorate diabetic cardiomyopathy in mice by inhibiting ferroptosis via the NRF2/HO-1 signaling pathway},
journal = {American Journal of Translational Research},
year = {2026},
volume = {18},
number = {2},
pages = {1719--1731},
doi = {10.62347/dlrz8628}
}
EUVIMED